Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self‐treating subjects

Peura, David A.; Riff, Dennis; Snoddy, Andrew M.; Fennerty, M. Brian

doi:10.1111/j.1365-2036.2009.04064.x

Cited by 21 publications

(23 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subjects treated with lansoprazole also experienced a higher mean percentage of nighttimes with no heartburn during the 14-day treatment period, compared with subjects on placebo (p<0.0001 for all doses vs placebo) (Figure 3) [41]. The results from these studies show that, compared with placebo, lansoprazole 15 mg and 30 mg are both efficacious for the treatment of frequent heartburn.…”

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 83%

“…Results from three studies described demonstrated that oncedaily lansoprazole 15 mg was effective and had a good tolerability profile in the treatment of frequent, including nighttime, heartburn in a self-treating population. [40,41] The 15-mg dose of lansoprazole, the lowest effective dose for acid-related gastrointestinal disorder symptoms, was shown to be as effective as the 30-mg dose. [41].…”

Section: Place Of Lansoprazole In the Management Of Heartburnmentioning

confidence: 99%

“…Two recently published reports of three multicenter, doubleblind, randomized studies, involving almost 2000 subjects, examined the effects of lansoprazole on daytime and nighttime frequent heartburn in self-treating populations [40,41]. In two studies, published in a single report, adults with frequent heartburn (on two or more days per week for the past month) were randomized to receive lansoprazole 15 mg or placebo for 14 days [40].…”

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 99%

“…In two studies, published in a single report, adults with frequent heartburn (on two or more days per week for the past month) were randomized to receive lansoprazole 15 mg or placebo for 14 days [40]. In the third study, subjects had to have heartburn on at least two nights per week, and they were randomized to receive lansoprazole 15 mg, lansoprazole 30 mg, or placebo each morning for 14 days [41].…”

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 99%

“…Dose-response data indicate that the incidence of diarrhea is dosedependent, remaining at 5% or less with lansoprazole doses up to 30 mg [24]. In general, adverse events experienced by patients on lansoprazole 15 mg and 30 mg are mild and transient [40,41].…”

Section: Safety Of Lansoprazolementioning

confidence: 99%

See 4 more Smart Citations

Knowledge and Usage Patterns of Folic Acid amongst Physician Assistant Students at the University of Texas Medical Branch at Galveston.

West¹,

Acosta

Reynado

et al. 2010

IJAPA

View full text Add to dashboard Cite

Purpose: Heartburn is a common symptom among adults, and can be troublesome when experienced more than two times a week. Heartburn and regurgitation are characteristic symptoms of gastroesophageal reflux disease, and may be experienced alone or in combination with other symptoms of reflux. The nurse practitioner should be aware of recent developments in the management of frequent heartburn that may be relevant to patients with this condition. Therefore the present review discusses the current treatment options for frequent heartburn with a focus on lansoprazole 15 mg, a recently approved over-the-counter proton pump inhibitor for frequent heartburn. Methods: The role of lansoprazole in the treatment of gastroesophageal reflux disease and heartburn was assessed using an online database search using PubMed, supplemented by the author's knowledge of the management of the disease.Conclusions: The management of frequent heartburn is an important issue for nurse practitioners. Available pharmacologic treatments include antacids, histamine 2 -receptor antagonists, and proton pump inhibitors. The latter are the agents of choice for treatment as they have been available by prescription for many years. These agents have proven efficacy and excellent safety and tolerability profiles. Lansoprazole has recently been approved for over-the-counter sale for the short-term (14 days) treatment of frequent heartburn.Implications for practice: Nurse practitioners should be aware of the evidence to support the change in status of lansoprazole from prescription to over-the-counter, in order to appropriately advise their patients.

show abstract

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 83%

Section: Place Of Lansoprazole In the Management Of Heartburnmentioning

confidence: 99%

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 99%

Section: Lansoprazole In the Treatment Of Acid-related Gastrointestinmentioning

confidence: 99%

Section: Safety Of Lansoprazolementioning

confidence: 99%

See 3 more Smart Citations

Knowledge and Usage Patterns of Folic Acid amongst Physician Assistant Students at the University of Texas Medical Branch at Galveston.

West¹,

Acosta

Reynado

et al. 2010

IJAPA

View full text Add to dashboard Cite

show abstract

Deprescribing versus continuation of chronic proton pump inhibitor use in adults

Boghossian

Rashid

Thompson

et al. 2017

Cochrane Database of Systematic Reviews

112

View full text Add to dashboard Cite

In people with mild GERD, on-demand deprescribing may lead to an increase in GI symptoms (e.g. dyspepsia, regurgitation) and probably a reduction in pill burden. There was a decline in participant satisfaction, although heterogeneity was high. There were insufficient data to make a conclusion regarding long-term benefits and harms of PPI discontinuation, although two trials (one on-demand trial and one abrupt discontinuation trial) reported endoscopic findings in their intervention groups at study end.

show abstract

Review of proton pump inhibitors for the initial treatment of heartburn: Is there a dose ceiling effect?

Kushner

Peura

2011

Adv Therapy

View full text Add to dashboard Cite

Proton pump inhibitors (PPIs) are widely used in clinical practice. However, concerns have been expressed about their long-term use, particularly with regard to bone health, Clostridium difficile infections, and drug interactions with platelet aggregation inhibitors. There has been limited guidance for clinicians concerning appropriate dose selection of PPIs for the initial treatment of heartburn. This review explored whether published clinical trials provide evidence of a ceiling above which higher PPI doses do not provide additional clinical benefit over the lowest approved dose. All articles of randomized, controlled clinical trials in nonerosive gastroesophageal reflux disease (GERD) in which the effects of two or more doses of the same PPI on symptomatic relief of heartburn were quantified as a study endpoint were identified and analyzed through PubMed searches up to the end of September 2010. The majority of trials evaluated provided no evidence that higher PPI doses were superior to the lowest approved dose for the initial treatment of heartburn. There were no clinically relevant findings with respect to dose dependence and safety outcomes in these studies. Efficacy outcomes from the trials suggest there may be a dose ceiling effect and highlight the need for further research on the use of the lowest effective PPI doses as an appropriate strategy in the initial treatment of uncomplicated heartburn. Observational studies and some meta-analyses have suggested that long-term PPI pharmacotherapy might be associated with safety concerns, which necessitate the periodic evaluation of therapeutic benefit in terms of symptom resolution and regimen tolerability. However, evidence to date suggests that use of the lowest effective dose for the indication is not associated with significant adverse events, particularly in the short term. Clinical practice suggests that patients requiring long-term treatment should be maintained on the lowest dose necessary to control symptoms, and monitored for potentially confounding factors that may lead to safety concerns.

show abstract

Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self‐treating subjects

Abstract: SUMMARY BackgroundFrequent nighttime heartburn is common. Lansoprazole 15 mg is indicated for treatment of heartburn and other gastro-oesophageal reflux disease-related symptoms.

Cited by 21 publications

References 18 publications

Knowledge and Usage Patterns of Folic Acid amongst Physician Assistant Students at the University of Texas Medical Branch at Galveston.

Knowledge and Usage Patterns of Folic Acid amongst Physician Assistant Students at the University of Texas Medical Branch at Galveston.

Deprescribing versus continuation of chronic proton pump inhibitor use in adults

Review of proton pump inhibitors for the initial treatment of heartburn: Is there a dose ceiling effect?

Contact Info

Product

Resources

About